Vistagen Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Vistagen Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join
The development tests whether Vistagen Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
The story matters when it changes Vistagen Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial
The story matters when it changes Vistagen Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript
Investors are testing whether Vistagen Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
Investors are testing whether Vistagen Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
Investors are testing whether Vistagen Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
Investors are testing whether Vistagen Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results
The story matters when it changes Vistagen Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest VTGN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Vistagen Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →